Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Amtrak train hits pickup truck in upstate New York, 3 dead including child
NEW YORK (AP) — A child was among the three victims killed when a passenger train hit a pickup truck2024-05-21Fishermen spot boat with 20 corpses floating off the coast of northeastern Brazil, reports say
BOGOTA, Colombia (AP) — A small boat full of decomposing corpses was spotted by fishermen off Brazil2024-05-21Hamas leader arrives in Cairo to hold talks on Gaza truce
(Xinhua) 08:52, February 21, 2024GAZA, Feb. 20 (Xinhua) -- Hamas leader Ismail Haniyeh on Tuesday ar2024-05-2112 feared killed as boat capsizes in India
(Xinhua) 09:46, January 19, 2024NEW DELHI, Jan. 18 (Xinhua) -- At least 12 people, including childre2024-05-21I was 'brokefished' by my friend for £400
I need your help. My friend K has been recently telling our friendship group about how dire his fina2024-05-21Yemeni gov't warns Houthis against military escalation in Red Sea
(Xinhua) 09:03, January 22, 2024ADEN, Yemen, Jan. 21 (Xinhua) -- The Presidential Leadership Council2024-05-21
atest comment